ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Monday.

ACAD has been the topic of a number of other research reports. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 12th. Needham & Company LLC reissued a “buy” rating and issued a $49.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 5th. ValuEngine raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $47.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 12th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. ACADIA Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $42.14.

ACADIA Pharmaceuticals (ACAD) opened at 30.03 on Monday. The firm’s market cap is $3.67 billion. The stock’s 50 day moving average is $28.13 and its 200 day moving average is $32.16. ACADIA Pharmaceuticals has a one year low of $20.68 and a one year high of $40.83.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.01. The business had revenue of $15.30 million for the quarter, compared to analyst estimates of $15.17 million. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. During the same quarter last year, the firm earned ($0.45) EPS. On average, analysts predict that ACADIA Pharmaceuticals will post ($2.82) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Upgraded by BidaskClub” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/26/acadia-pharmaceuticals-inc-acad-stock-rating-upgraded-by-bidaskclub.html.

In other news, EVP Glenn Baity sold 1,903 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $30.00, for a total transaction of $57,090.00. Following the sale, the executive vice president now owns 83,059 shares of the company’s stock, valued at approximately $2,491,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 22.25% of the company’s stock.

Large investors have recently bought and sold shares of the company. Stifel Financial Corp raised its stake in ACADIA Pharmaceuticals by 3.1% in the first quarter. Stifel Financial Corp now owns 8,708 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 260 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 510 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares during the last quarter. Creative Planning raised its stake in ACADIA Pharmaceuticals by 4.9% in the second quarter. Creative Planning now owns 24,915 shares of the biopharmaceutical company’s stock valued at $695,000 after buying an additional 1,159 shares during the last quarter. Finally, Geneva Advisors LLC raised its stake in ACADIA Pharmaceuticals by 8.4% in the first quarter. Geneva Advisors LLC now owns 18,002 shares of the biopharmaceutical company’s stock valued at $619,000 after buying an additional 1,396 shares during the last quarter. 97.18% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.